Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

11.80 +0.42 (+3.69%)
Streaming Delayed Price Updated: 3:32 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Why Is Novavax (NVAX) Stock Rallying Today? ↗
Novavax (NVAX) stock is taking off on Tuesday after the vaccine company got approval for the expanded use of its Covid-19 vaccine in Europe. 
Via InvestorPlace
News headline image
Amylyx (AMLX) Stock Spikes 13% as FDA Resumes Discussion of ALS Drug ↗
A new wrinkle in the story of Amylyx Pharmaceuticals' ongoing battle against ALS bodes well for patients, and for AMLX stock holders. 
Via InvestorPlace
News headline image
Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Ra Medical Systems, Inc. (NASDAQ: RMED) shares jumped 69.6% to $0.5240 after the company announced it has received FDA 510(k) clearance for its DABRA 2.0 catheter. 
Via Benzinga
News headline image
Here's How Citi Views Amylyx Pharma ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Amylyx Pharma ↗
Within the last quarter, Amylyx Pharma (NASDAQ:AMLX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Why Stealth BioTherapeutics Shares Are Surging Today? ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before. 
Via Investor's Business Daily
News headline image
Canada Approves Amylyx's ALS Drug; FDA To Consider Approval In September ↗
The Canadian government has given its approval to AMX0035, a new drug from Cambridge, Massachusetts-based Amylyx Pharmaceuticals Inc. 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
Via FinancialNewsMedia
News headline image
Mid-Afternoon Market Update: Gold Drops 1%; Sprague Resources Shares Spike Higher ↗
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 300 points on Friday. 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Shares Shoot Up As FDA Extends Review Of NDA For Neurodegenerative Disease Candidate ↗
The U.S. Food and Drug Administration (FDA) has extended the review of New Drug Application (NDA) by three months, submitted by Amylyx Pharmaceuticals (NASDAQ: AMLX) for its lead drug candidate AMX0035... 
Via Benzinga
News headline image
82 Biggest Movers From Yesterday ↗
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday. 
Via Benzinga
News headline image
Novavax (NVAX) Stock Falls 25% on FDA Heart Inflammation Warning ↗
Novavax (NVAX) stock is falling on Friday after the FDA requested a heart inflammation warning for the company's Covid-19 vaccine. 
Via InvestorPlace
News headline image
83 Biggest Movers From Yesterday ↗
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly... 
Via Benzinga
News headline image
69 Biggest Movers From Friday ↗
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
News headline image
Mid-Day Market Update: Nasdaq Down 300 Points; Turning Point Therapeutics Shares Jump ↗
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping more than 300 points on Friday. 
Via Benzinga
News headline image
40 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share. 
Via Benzinga
News headline image
Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 23% Today? ↗
Amylyx Pharmaceuticals (AMLX) stock is rising higher on Friday following an update from the U.S. Food and Drug Administration (FDA). 
Via InvestorPlace
News headline image
Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May ↗
U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Friday. 
Via Benzinga
News headline image
Former Red-Hot IPO Amylyx Soars On New Hopes For Its ALS Drug ↗
The FDA pushed its review date for Amylyx Pharmaceuticals' controversial ALS treatment on Friday, and the biotech stock skyrocketed. 
Via Investor's Business Daily
News headline image
Here's Why Amylyx Pharmaceuticals Shares Are Skyrocketing Today ↗
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) shares are trading higher by 37.67% at $13.45 after the company announced the FDA extended the review timeline of the New Drug... 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022 ↗
Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of... 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
92 Biggest Movers From Friday ↗
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.